In August 2009, Gamma-Dynacare Medical Laboratories began testing for Chlamydia trachomatis and Neisseria gonorrhoeae (GC) with one sample, either GenProbe Unisex swab or urine. Because the Gen-Probe Nucleic Acid-based assay represents an improvement over culture, we plan to discontinue routine testing for GC on vaginal swabs, effective July 5, 2010. For more information, please see the Client Notice below.

Client Notice - Urogenital Syndromes - June 23, 2010

In August 2009, Gamma-Dynacare Medical Laboratories began testing for Chlamydia trachomatis and Neisseria gonorrhoeae (GC) with one sample, either GenProbe Unisex swab or urine. Because the Gen-Probe Nucleic Acid-based assay represents an improvement over culture, we plan to discontinue routine testing for GC on vaginal swabs, effective July 5, 2010. For more information, please see the Client Notice below.

Client Notice - Urogenital Syndromes - June 23, 2010

Gamma-Dynacare is in the process of converting to the use of safety-engineered needles for blood collection.  Effective immediately, when you request blood collection needles, we will be issuing the BD Eclipse safety-engineered needles. We are currently updating our supply requisitions accordingly. After July 1, please return any unused boxes of conventional needles to us.  For more information, please see the Client Notice below.

Client Notice-Introduction of Safety-Engineered Needles-June 17, 2010

Gamma-Dynacare is in the process of converting to the use of safety-engineered needles for blood collection.  Effective immediately, when you request blood collection needles, we will be issuing the BD Eclipse safety-engineered needles. We are currently updating our supply requisitions accordingly. After July 1, please return any unused boxes of conventional needles to us.  For more information, please see the Client Notice below.

Client Notice-Introduction of Safety-Engineered Needles-June 17, 2010

During the month of July, Gamma-Dynacare Medical Laboratories will be phasing in a thoroughly evaluated new Immunoassay analyzer. The introduction of the Roche E170 methodology will result in changes to some reference intervals. These changes are summarized in the Client Notice below and the new reference intervals will be clearly indicated on patient reports.

Client Notice-Roche Modular Automation System-June 10, 2010 [PDF]

During the month of July, Gamma-Dynacare Medical Laboratories will be phasing in a thoroughly evaluated new Immunoassay analyzer. The introduction of the Roche E170 methodology will result in changes to some reference intervals. These changes are summarized in the Client Notice below and the new reference intervals will be clearly indicated on patient reports.

Client Notice-Roche Modular Automation System-June 10, 2010 [PDF]

As documented in published recommendations and literature, the time that tissues are immersed in 10% Neutral Buffered Formalin affects the reactivity of many antigens detected using immunohistochemistry (IHC). Therefore, to ensure optimal quality, when completing the Histopathology Requisition Form, it is essential that you indicate the date and time that the specimen was placed into 10% Neutral Buffered Formalin. For more information, please see the Client Notice below.

Client Notice-Formalin Fixation Time and Immunohistochemistry-June 1, 2010 [PDF]

As documented in published recommendations and literature, the time that tissues are immersed in 10% Neutral Buffered Formalin affects the reactivity of many antigens detected using immunohistochemistry (IHC). Therefore, to ensure optimal quality, when completing the Histopathology Requisition Form, it is essential that you indicate the date and time that the specimen was placed into 10% Neutral Buffered Formalin. For more information, please see the Client Notice below.

Client Notice-Formalin Fixation Time and Immunohistochemistry-June 1, 2010 [PDF]